Literature DB >> 10406992

Alterations of muscarinic acetylcholine receptor subtypes in diffuse lewy body disease: relation to Alzheimer's disease.

K Shiozaki1, E Iseki, H Uchiyama, Y Watanabe, T Haga, K Kameyama, T Ikeda, T Yamamoto, K Kosaka.   

Abstract

OBJECTIVES: Dementia associated with Lewy bodies in cortical and subcortical areas is classified as dementia of the non-Alzheimer type and termed diffuse Lewy body disease (DLBD). The generic term "dementia with Lewy bodies (DLB)" was proposed in the international workshop on Lewy body dementia to include the similar disorders presenting Lewy bodies. In DLB, a lower level of choline acetyltransferase (ChAT) activity in the neocortex was found compared with that in Alzheimer's disease. The purpose of the present study was to determine the total amount of muscarinic acetylcholine receptors (mAChRs) and relative proportion of each subtype (m1-m4) of mAChRs in the frontal and temporal cortex of seven DLBD and 11 Alzheimer's disease necropsied brains.
METHODS: A [(3)H]quinuclidinyl benzilate (QNB) binding assay and an immunoprecipitation assay using subtype-specific antibodies were performed. Each antibody was raised against fusion proteins containing peptides corresponding to the third intracellular (i3) loops of the respective mAChR subtype.
RESULTS: The total amounts of mAChRs were significantly lower in the preparations of temporal cortices from DLBD and Alzheimer's disease than in those from dead controls (seven cases). In both diseases, the proportion of the m3 receptor in the frontal cortex was significantly increased and that of the m4 receptor in the temporal cortex was significantly decreased compared with the control specimens. The proportions of the m1 and m2 subtypes were significantly different in the temporal cortex. The proportion of the m1 receptor was significantly greater in the DLBD brains, whereas that of the m2 receptor was significantly greater in the Alzheimer's disease brains than in the controls.
CONCLUSIONS: The m1 receptor is the major subtype in the cerebral cortex, and m2 is known to be present at presynaptic terminals. The higher proportions of m1 in DLBD and m2 in Alzheimer's disease suggest that the manner of degeneration in the cholinergic system is different between the diseases. It is hypothesised that a severe depletion of presynaptic cholinergic projective neurons causes the upregulation of m1 receptor in the temporal cortex in DLBD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10406992      PMCID: PMC1736504          DOI: 10.1136/jnnp.67.2.209

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  15 in total

1.  Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease.

Authors:  Cassia R Overk; Christian C Felder; Yuan Tu; Doug A Schober; Kelly R Bales; Joanne Wuu; Elliott J Mufson
Journal:  J Chem Neuroanat       Date:  2010-03-27       Impact factor: 3.052

2.  [Dementia with Lewy bodies. Clinical improvement under treatment with an acetylcholinesterase inhibitor].

Authors:  M Omerovic; S J Teipel; T Hampel
Journal:  Nervenarzt       Date:  2007-09       Impact factor: 1.214

3.  Motor cortex inhibitory circuits in dementia with Lewy bodies and in Alzheimer's disease.

Authors:  R Nardone; A Bratti; F Tezzon
Journal:  J Neural Transm (Vienna)       Date:  2006-10-06       Impact factor: 3.575

4.  Regional covariance of muscarinic acetylcholine receptors in Alzheimer's disease using (R, R) [(123)I]-QNB SPECT.

Authors:  Sean J Colloby; Ian G McKeith; David J Wyper; John T O'Brien; John-Paul Taylor
Journal:  J Neurol       Date:  2015-06-30       Impact factor: 4.849

5.  Diffuse Lewy Body Disease.

Authors:  Theresa A. Zesiewicz; Matthew J. Baker; Peter B. Dunne; Robert A. Hauser
Journal:  Curr Treat Options Neurol       Date:  2001-11       Impact factor: 3.598

Review 6.  Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD.

Authors:  Paul T Francis
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

Review 7.  Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management.

Authors:  Clive Ballard; Dag Aarsland; Paul Francis; Anne Corbett
Journal:  Drugs Aging       Date:  2013-08       Impact factor: 3.923

Review 8.  Benefit-risk considerations in the treatment of dementia with Lewy bodies.

Authors:  Margaret M Swanberg; Jeffrey L Cummings
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

9.  Parasympathetic modulation of local acute inflammation in murine submandibular glands.

Authors:  Alejandro J Español; Eulalia de la Torre; María Elena Sales
Journal:  Inflammation       Date:  2003-04       Impact factor: 4.092

10.  Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) 123I-QNB SPECT.

Authors:  Sanjeet Pakrasi; Sean J Colloby; Michael J Firbank; Elaine K Perry; David J Wyper; Jonathan Owens; Ian G McKeith; E David Williams; John T O'Brien
Journal:  J Neurol       Date:  2007-03-14       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.